COVID-19: clinical presentation and detection methods

Pradhan, Madhulika; Shah, Kamal; Alexander, Amit; AJAZUDDIN, .; Minz, Sunita; Singh, Manju Rawat; Singh, Deependra; Yadav, Krishna; Chauhan, Nagendra Singh

doi:10.1080/15321819.2021.1951291

Cited by 39 publications

(26 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, some variation in seroprevalence was also noted in our study, in particular, depending on the type of test used, from 2% for qualitative tests to 16% for quantitative serological tests. This difference could be related to the preferential use of quantitative tests in case of suspected infection, due to their higher sensibility compared to qualitative tests [25]. In particular, the percentage of seroprevalence was found to be 14.9% for only the IgG antibodies from quantitative tests.…”

Section: Discussionmentioning

confidence: 95%

Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy

Paduano

Galante

Berselli

et al. 2022

IJERPH

View full text Add to dashboard Cite

Italy was the first Western European country to be severely hit by the COVID-19 pandemic. Variations in seroprevalence rates were reported according to geographical and temporal differences of previous surveys, as well as depending on demographic and occupational factors. In this cross-sectional study, we evaluated the prevalence of anti-SARS-CoV-2 antibodies in a population of the Emilia-Romagna region in Northern Italy after the first wave in the period from 26 September 2020–26 March 2021. We included 5128 subjects who voluntarily underwent serological tests to determine anti-SARS-CoV-2 antibody positivity, including both self-referred individuals (24.2%) and workers adhering to company screening programs (76.8%). Overall, seroprevalence was 11.3%, higher in self-referred (13.8%) than employed-referred (10.5%) individuals. A slightly higher seroprevalence emerged in women compared to men (12.3% and 10.7%), as well as in the extreme age categories (18.6% for 60–69 years, 18.0% for ≥70 years, and 17.1% for <20 years compared to 7.6% for 20–39 years). Healthcare professionals showed the highest prevalence of seropositivity (22.9%), followed by workers in direct contact with customers, such as the communication, finance, and tourism sectors (15.7%). Overall subgroups seroprevalence increased compared to the first wave data but the trends agreed between the first and subsequent waves, except for an increase in the younger age group and in the sector in direct contact with customers. Among the occupational categories, our study confirms that healthcare workers and workers in the sports sector were at high risk of exposure to SARS-CoV-2.

show abstract

Section: Discussionmentioning

confidence: 95%

Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy

Paduano

Galante

Berselli

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Despite of the un-availability of proper medications against COVID-19, some antivirals/antibiotics were repurposed against the pandemic. The drugs being appraised towards COVID-19 management comprised of antibodies (e.g., hyper immune immunoglobulins and convalescent plasma), antivirals (e.g., favipiravir and remdesivir), targeted immunomodulatory therapies (e.g., anakinra, ruxolitinib, tocilizumab and sarilumab), anti-inflammatory agents (e.g., statins and dexamethasone), anticoagulants (e.g., heparin), and anti fibrotics (e.g., tyrosine kinase inhibitors) [ [12] , [13] , [14] , [15] , [16] ] along with numerous supportive care rudiments such as supplementary oxygen and corticosteroids ( Fig. 2b , Fig.…”

Section: The Current Investigational Diagnostic and Therapeutic Measu...mentioning

confidence: 99%

Theranostic efficiency of biosurfactants against COVID-19 and similar viruses - A review

Sarangi¹,

Padhi²,

Patel

et al. 2022

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

“…The current statistics of the World Health Organization indicate that there are 476,374,234 confirmed cases with COVID19 and 6,108,976 deaths around the world [ 1 , 2 ]. The respiratory symptoms range from asymptomatic to severe conditions, which most common symptoms are dry cough, high fever, loss of taste and smell, and less common symptoms are vomiting, diarrhea, headache, myalgia, nausea and sputum production [ 3 ]. Advanced affected cases of COVID19 cause many complications such as ventilator dependence, oxygen dependence and fibrotic lung disease.…”

Section: Introductionmentioning

confidence: 99%